Abstract:Background: The VeriStrat test, a blood-based proteomic test utilizing MALDI-ToF mass spectrometry, employs machine learning for prognostic assessment in non-small-cell lung cancer (NSCLC) across various stages, histologies, and treatments. Recently, its prognostic utility has extended to patients undergoing immune checkpoint inhibitor (ICI) treatment. Yet, the influence of treatment regimen and PD-L1 levels on its prognostic power remains less explored. Methods: In this retrospective study, 174 NSCLC patients receiving ICI monotherapy (ICI mono) or combination with chemotherapy (combination) underwent VeriStrat testing from 2016 to 2023. Blood sample spectra categorized patients into VeriStrat 'Good' (VS-G) or VeriStrat 'Poor' (VS-P) groups. Overall survival (OS) and progression-free survival (PFS) were calculated using the log-rank test for the first ICI-containing regimen post-serum sample draw. Results: Among 174 patients, 97 received combination therapy, and 77 received ICI alone. Within the 99 patients with PD-L1 levels <50%, 38 patients received IO monotherapy (23 pts for standard of care, 5 pts for poor candidacy for chemotherapy, 5 pts for clinical trial, 3 pts for patient refusal, and 2 pts for physician discretion). Survival analysis results are presented in Table 1. Survival analysis by treatment regimen and PD-L1 level Hazard Ratio VS-G/VS-P 95% CI p-value ipilimumab+nivolumab PFS 0.57 0.04-7.89 0.52 Total n=22 VS-G n=19 VS-P n=3 OS 0.33 0.03-3.47 0.11 pembrolizumab PFS 0.90 0.19-4.31 0.88 Total n=25 VS-G n=20 VS-P n=5 OS 0.33 0.08-1.43 0.01* carboplatin+pemetrexed+pembrolizumab PFS 0.45 0.17-1.19 0.02* Total n=41 VS-G n=30 VS-P n=11 OS 0.61 0.22-1.68 0.27 PD-L1>=50 PFS 0.93 0.34-2.54 0.89 Total n=39 VS-G n=29 VS-P n=10 OS 0.45 0.17-1.20 0.18 PD-L1 =50 + ICI mono PFS 0.55 0.12-2.65 0.69 Total n=23 VS-G n=18 VS-P n=5 OS 1.25 0.32-4.96 0.75 PD-L1<50 + ICI mono PFS 0.77 1.15-3,91 0.70 Total n=37 VS-G n=30 VS-P n=7 OS 0.24 0.51-1.10 0.0004* Hazard Ratio combination/ICI mono 95% CI p-value PD-L1<50 +VS-G OS 0.70 0.36-1.33 0.24 Total n=76 ICI mono n=30 Combination n=46 PD-L1 =50 +VS-G OS 2.18 0.69-6.90 0.27 Total n=29 ICI mono n=22 Combination n=7 PD-L1>=50 +VS-P OS NA NA 0.21 Total n=10 ICI mono n=3 Combination n=7 Conclusions: Our findings suggest that the prognostic value of the VeriStrat test may vary based on the treatment regimen. In clinical scenarios utilizing ICI monotherapy for patients with PD-L1 levels <50%, the role of VeriStrat seems more significant. A prospective study with a larger sample size for validation is warranted. Citation Format: Leeseul Kim, Taegyu Um, Young Kwang Chae, Allen Cho. Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7099.

Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

Prognostic and Predictive Value of Serum Carcinoembryonic Antigen Levels in Advanced Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Sensitive Mutations and Receiving Tyrosine Kinase Inhibitors.

Impact of Serum Vascular Endothelial Growth Factor and Interleukin-6 on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-cell Lung Cancer

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes after Treatment with EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Prediction of Epidermal Growth Factor Receptor Mutations in the Plasma/pleural Effusion to Efficacy of Gefitinib Treatment in Advanced Non-Small Cell Lung Cancer.

Abstract 7099: Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels

Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.

Does Selected Immunological Panel Possess the Value of Predicting the Prognosis of Early-Stage Resectable Non-Small Cell Lung Cancer?

Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors by proteomic analysis.

Preliminary Analysis of Biomarkers in Plasma by Seldi to Predict the Response to Egfr Tyrosine Kinase Inhibitors (tkis) in Nsclc Patients.

Serum CEA and CYFRA21-1 correlates with EGFR mutation and EGFR-TKI effectiveness in untreated NSCLC patients

Evaluation of the VeriStrat® Serum Protein Test in Patients with Advanced Squamous Cell Carcinoma of the Lung Treated with Second-Line Afatinib or Erlotinib in the Phase III LUX-Lung 8 Study

Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations

The predictive value of serum tumor markers for EGFR mutation in non-small cell lung cancer patients with non-stage IA

Reliability of Using Circulating Tumor Cells for Detecting Epidermal Growth Factor Receptor Mutation Status in Advanced Non-Small-cell Lung Cancer Patients: a Meta-Analysis and Systematic Review

A Retrospective Analysis Of The Icogen Clinical Trial Demonstrates The Utility Of Veristrat To Predict Outcome In An All Chinese Cohort Treated With Egfr Tki.

The Impact of Epidermal Growth Factor Receptor Mutations on the Prognosis of Resected Non-Small Cell Lung Cancer: a Meta-Analysis of Literatures.